Method for inducing differentiation of mesodermal stem cells, es cells, or immortalized mesodermal stem cells into neural cells
CA 2465653 C · Owner: Aska Pharmaceutical Co. Ltd. · Inventors: Hamada, Hirofumi; Honmou, Osamu
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Mesodermal stem cells or ES cells, prepared from the mononuclear cell fraction isolated from bone marrow fluid or umbilical blood were found to , differentiate into neural stem cells, neurons, or glial cells when cultured in a basal culture medium. In addition, the , differentiation of the mesodermal stem cells or ES cells into neural cells was promoted , through the addition of an ischemic brain extract to the above-mentioned basal culture , medium. Furthermore, the neural cells obtained using the above-described method for , inducing differentiation were revealed to have neural regeneration potency in a brain , infarction model, a dementia model a spinal cord injury model and a , …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 30, 2002 and granted October 8, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 30, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 30, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.